文献速递妇科肿瘤

英国家族性卵巢癌筛查研究II期:卵巢癌诊断分期偏移的证据

Evidence of Stage Shift in Women Diagnosed With Ovarian Cancer During Phase II of the United Kingdom Familial Ovarian Cancer Screening Study.
PubMed 文献 · J Clin Oncol · 2017-02-27

该研究在英国42个中心招募 lifetime 风险≥10%的女性,每4个月行ROCA筛查联合经阴道超声,评估筛查性能。共4348名女性接受13728人年筛查,中位随访4.8年。1年内诊断19例侵袭性卵巢癌/输卵管癌,其中52.6%为I-II期;筛查敏感性94.7%,阳性预测值10.8%,阴性预测值100%。结论认为ROCA筛查是高危女性推迟或拒绝RRSO的一种选择,但能否改善生存尚不清楚。

要点

  • 高危女性每4个月ROCA筛查联合经阴道超声,1年内卵巢癌/输卵管癌检出敏感性94.7%。
  • 1年内诊断的19例中52.6%为I-II期,筛查后1年以上诊断的18例中仅5.6%为I-II期(P<.001)。
  • 筛查阳性预测值10.8%,阴性预测值100%;能否改善生存尚不清楚。

核心结论

  • 基于ROCA的筛查是高危女性推迟或拒绝RRSO时的一种选择,因其敏感性高且存在显著分期偏移。
  • 该策略能否改善筛查高危女性的生存尚不清楚。

研究设计与样本

  • 前瞻性研究,在英国42个中心招募估计 lifetime 卵巢癌/输卵管癌风险≥10%的女性。
  • 每4个月行ROCA筛查,ROCA正常者每年行经阴道超声,ROCA异常者2个月内行经阴道超声。
  • 研究期间鼓励行降低风险的输卵管卵巢切除术(RRSO)。
  • 2007年6月14日至2012年5月15日共4348名女性接受13728人年筛查,中位随访4.8年。

主要发现

  • 19例在既往筛查后1年内诊断侵袭性卵巢癌/输卵管癌,其中13例筛查检出、6例RRSO时隐匿发现;无症状间期癌为零。
  • 19例中10例(52.6%,CI 28.9%-75.6%)为I-II期;筛查检出的13例中5例(38.5%,CI 13.9%-68.4%)为I-II期;6例隐匿癌中5例(83.3%,CI 35.9%-99.6%)为I-II期。
  • 1年内检出卵巢癌/输卵管癌的模型化敏感性94.7%(CI 74.0%-99.9%)、阳性预测值10.8%(CI 6.5%-16.5%)、阴性预测值100%(CI 100%-100%)。
  • 既往筛查后1年内诊断的19例中7例(36.8%,CI 16.3%-61.6%)为IIIb-IV期,筛查结束后1年以上诊断的18例中17例(94.4%,CI 72.7%-99.9%)为IIIb-IV期(P<.001)。
  • 既往筛查后1年内诊断的19例中18例(94.8%,CI 74.0%-99.9%)无残留病灶(手术复杂性较低,P=.16),后续诊断的18例中13例(72.2%,CI 46.5%-90.3%)无残留病灶(P=.09)。

关键数值与推荐

  • 筛查对象为估计 lifetime 卵巢癌/输卵管癌风险≥10%的女性。
  • ROCA筛查间隔为每4个月一次。
  • 经阴道超声每年一次(ROCA正常)或ROCA异常后2个月内进行。

临床怎么用

  • 作者认为,基于ROCA的筛查是高危女性推迟或拒绝RRSO时的一种选择。
  • 作者指出,该策略能否改善筛查高危女性的生存尚不清楚。

局限性

  • 作者指出,该策略能否改善筛查高危女性的生存尚不清楚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose To establish the performance of screening with serum cancer antigen 125 (CA-125), interpreted using the risk of ovarian cancer algorithm (ROCA), and transvaginal sonography (TVS) for women at high risk of ovarian cancer (OC) or fallopian tube cancer (FTC). Patients and Methods Women whose estimated lifetime risk of OC/FTC was ≥ 10% were recruited at 42 centers in the United Kingdom and underwent ROCA screening every 4 months. TVS occurred annually if ROCA results were normal or within 2 months of an abnormal ROCA result. Risk-reducing salpingo-oophorectomy (RRSO) was encouraged throughout the study. Participants were observed via cancer registries, questionnaires, and notification by centers. Performance was calculated after censoring 365 days after prior screen, with modeling of occult cancers detected at RRSO. Results Between June 14, 2007, and May 15, 2012, 4,348 women underwent 13,728 women-years of screening. The median follow-up time was 4.8 years. Nineteen patients were diagnosed with invasive OC/FTC within 1 year of prior screening (13 diagnoses were screen-detected and six were occult at RRSO). No symptomatic interval cancers occurred. Ten (52.6%) of the total 19 diagnoses were stage I to II OC/FTC (CI, 28.9% to 75.6%). Of the 13 screen-detected cancers, five (38.5%) were stage I to II (CI, 13.9% to 68.4%). Of the six occult cancers, five (83.3%) were stage I to II (CI, 35.9% to 99.6%). Modeled sensitivity, positive predictive value, and negative predictive value for OC/FTC detection within 1 year were 94.7% (CI, 74.0% to 99.9%), 10.8% (6.5% to 16.5%), and 100% (CI, 100% to 100%), respectively. Seven (36.8%) of the 19 cancers diagnosed < 1 year after prior screen were stage IIIb to IV (CI, 16.3% to 61.6%) compared with 17 (94.4%) of 18 cancers diagnosed > 1 year after screening ended (CI, 72.7% to 99.9%; P < .001). Eighteen (94.8%) of 19 cancers diagnosed < 1 year after prior screen had zero residual disease (with lower surgical complexity, P = .16) (CI, 74.0% to 99.9%) compared with 13 (72.2%) of 18 cancers subsequently diagnosed (CI, 46.5% to 90.3%; P = .09). Conclusion ROCA-based screening is an option for women at high risk of OC/FTC who defer or decline RRSO, given its high sensitivity and significant stage shift. However, it remains unknown whether this strategy would improve survival in screened high-risk women.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Rosenthal AN, Fraser LSM, Philpott S, et al. Evidence of Stage Shift in Women Diagnosed With Ovarian Cancer During Phase II of the United Kingdom Familial Ovarian Cancer Screening Study. J Clin Oncol. 2017. PMID: 28240969. doi:10.1200/JCO.2016.69.9330

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。